SHERIDAN, WYOMING – November 07, 2024 – Roche, a global pioneer in pharmaceuticals and diagnostics, is set to present a robust body of data at the upcoming 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego. With more than 40 abstracts spanning nine blood disorders, Roche's presence at ASH underscores its unwavering dedication to improving outcomes for individuals battling lymphoma.
The company will unveil significant findings from studies evaluating its innovative lymphoma treatments, including Polivy® (polatuzumab vedotin), Lunsumio® (mosunetuzumab), and Columvi® (glofitamab), along with exciting new investigational combination data.
Key Highlights from Roche's ASH 2024 Presentations:
*Polivy Continues to Impress in Diffuse Large B-Cell Lymphoma (DLBCL): Five-year data from the pivotal Phase III POLARIX study (abstract #469) further solidify Polivy's role in transforming the treatment landscape for DLBCL. Combined with MabThera®/Rituxan® (rituximab) and standard chemotherapy (R-CHP), Polivy demonstrates the potential for long-lasting remissions and, for the first time, shows a positive trend in overall survival (OS) for patients with newly diagnosed DLBCL. This is a major milestone in a disease area that has seen limited progress for nearly two decades.
Lunsumio and Columvi Demonstrate Long-Term Benefits:Extended follow-up data from the GO29781 study of Lunsumio (abstract #4407) and the NP30179 study of Columvi (abstract #865) provide compelling evidence of the sustained benefits these fixed-duration bispecific antibodies offer. In patients with relapsed or refractory follicular lymphoma (FL) and DLBCL, respectively, Lunsumio and Columvi have shown durable remissions and immune system recovery even after treatment completion. This reinforces their value in the third-line or later treatment setting.
*Subcutaneous Lunsumio Offers Enhanced Convenience: For the first time, Roche will present data on a subcutaneous formulation of Lunsumio from the pivotal Phase II GO29781 study (abstract #1645). This new formulation has demonstrated high response rates and a favorable safety profile in individuals with relapsed or refractory FL. "Subcutaneously administered Lunsumio could further improve the patient experience by combining shorter administration time with the existing benefits of a fixed-duration and outpatient therapy," notes the company.
Columvi Combination Maintains Quality of Life: New patient-reported outcomes from the Phase III STARGLO study (abstract #5132) reveal that the Columvi combination, despite involving a higher number of treatment cycles, does not compromise patients' health-related quality of life. This finding, coupled with the significant improvement in OS observed in the study, further supports Columvi's potential to benefit patients with relapsed or refractory DLBCL.
Investigational Combinations Pave the Way for Future Advancements:** Roche continues to explore the potential of combining Polivy with its novel bispecific antibodies, Lunsumio and Columvi, in earlier lines of therapy for relapsed or refractory DLBCL. Data from the Phase Ib/II NP39488 (abstract #988) and Phase II GO40516 (abstract #989) studies contribute to the growing evidence supporting the use of these combinations and their ongoing Phase III development.
Roche's commitment to advancing lymphoma care is evident in the breadth and depth of research presented at ASH 2024. These data offer renewed hope for patients and underscore the transformative potential of Roche's innovative therapies in the fight against lymphoma.